Ftse Mib
33.494,83
0,60%
DAX
19.322,59
0,91%
S&P 500
5.969,34
0,35%
NASDAQ
19.003,65
0,16%
Bitcoin
98.515,82
-0,52%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Ultragenyx Pharmaceutical Inc (RARE) Ultragenyx Pharmaceutical Inc (RARE) Notizie

Ultragenyx Pharmaceutical Inc

RARE
47,24
1,22 (2,65%)
22 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
20/11/202422:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
12/11/202412:03EDGAR2Form 8-K - Current report
09/11/202416:30GLOBEUltragenyx Presents Positive Update on GTX-102 Angelman..
05/11/202422:06EDGAR2Form 8-K - Current report
05/11/202422:01GLOBEUltragenyx Reports Third Quarter 2024 Financial Results and..
29/10/202421:05GLOBEUltragenyx to Host Conference Call for Third Quarter 2024..
18/10/202422:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
11/10/202422:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/10/202414:15EDGAR2Form 8-K - Current report
07/10/202414:00GLOBEUltragenyx Receives Breakthrough Therapy Designation for..
03/10/202422:34EDGAR2Form 8-K - Current report
03/10/202422:30GLOBEUltragenyx Provides Update on Stage 1 Cohorts in Pivotal..
26/9/202414:00GLOBEUltragenyx Announces Upcoming Setrusumab (UX143)..
18/9/202423:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
18/9/202419:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202417:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202422:30GLOBEUltragenyx to Participate in Investor Conferences in..
23/8/202413:00BWTactical Resources, a Growing North American Rare Earth..
21/8/202422:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
01/8/202422:07EDGAR2Form 8-K - Current report
01/8/202422:05GLOBEUltragenyx Reports Second Quarter 2024 Financial Results and..
25/7/202422:05GLOBEUltragenyx to Host Conference Call for Second Quarter 2024..
24/7/202414:00GLOBEUltragenyx to Present GTX-102 Angelman Syndrome Program..
19/7/202422:05GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
17/7/202422:06EDGAR2Form 8-K - Current report
17/7/202422:05GLOBEUltragenyx Announces Successful End-of-Phase 2 Meeting with..
12/7/202422:04EDGAR2Form S-8 - Securities to be offered to employees in employee..
20/6/202422:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
20/6/202420:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/6/202420:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/6/202420:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202412:31EDGAR2Form 8-K - Current report
14/6/202423:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/6/202402:49GLOBEUltragenyx Announces Pricing of Public Offering of Common..
13/6/202401:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202423:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/6/202423:10EDGAR2Form 144 - Report of proposed sale of securities
12/6/202422:05GLOBEUltragenyx Announces Proposed Public Offering of Common..
12/6/202422:04EDGAR2Form 8-K - Current report
12/6/202422:00GLOBEUltragenyx Announces Plans to File for Accelerated Approval..
11/6/202423:47GLOBEUltragenyx and Mereo BioPharma Announce New Phase 2 Data..
11/6/202401:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/6/202423:20EDGAR2Form 144 - Report of proposed sale of securities
04/6/202422:05GLOBEUltragenyx to Participate at Goldman Sachs 45th Annual..
30/5/202422:04EDGAR2Form 8-K - Current report
30/5/202422:00GLOBEUltragenyx Announces Positive Top-Line Results from Phase 3..
17/5/202422:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
07/5/202422:30GLOBEUltragenyx to Participate at Bank of America’s 2024..
02/5/202422:00GLOBEUltragenyx Reports First Quarter 2024 Financial Results and..
30/4/202422:00GLOBEUltragenyx Issues 2023 Corporate Responsibility Report,..
Apertura: 46,07 Min: 45,47 Max: 47,47
Chiusura: 46,02

La tua Cronologia

NASDAQ
RARE
Ultragenyx Pharmaceutical
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network